ACADIA Pharmaceuticals Reports Third Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to ACADIA Pharmaceuticals Reports Third Quarter 2015 Financial Results
November 6, 2015 12:00 PM EST
Cowen analyst Ritu Baral reiterated an Outperform rating and $50 price target on Acadia Pharmaceuticals (NASDAQ: ACAD) following Q3 results with all eyes on PDP PDUFA and ADP enrollment.
Baral commented, "ACAD reported 3Q15 earnings and elaborated on initial steps for upcoming commercial... More
November 6, 2015 9:43 AM EST
Piper Jaffray downgraded Acadia Pharmaceuticals (NASDAQ: ACAD) from Overweight to Neutral with a price target of $39.00 (from $48.00).
Analyst Charles Duncan commented, "We're downgrading to Neutral following program updates that lower our conviction on near-term upside from the pima pipeline. New concerns center on a... More
November 5, 2015 4:13 PM EST
Acadia Pharma (NASDAQ: ACAD) reported Q3 EPS of ($0.39), $0.01 better than the analyst estimate of ($0.40).
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
...
More
